Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 5 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Transperitoneal versus retroperitoneal laparoscopic nephroureterectomy: a meta-analysis of technical approaches for upper tract urothelial carcinoma.Langenbeck's archives of surgery · 2025Pooled it
- Metabolomics and metabolites in cancer diagnosis and treatment.Molecular biomedicine · 2025Pooled it
- The efficacy of neoadjuvant therapy for upper tract urothelial carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis.World journal of urology · 2024Pooled it
- Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.The Journal of urology · 2013Pooled it
- A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma.The Journal of urology · 2025Trial
- Real-world perioperative systemic treatment patterns and postoperative mortality in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy in Japan: WAKKA-UTUC study.International journal of clinical oncology · 2026Article
- Occult pT2-4 disease and postoperative loss of full-dose cisplatin eligibility in CT-staged cT≤1/cN0 upper tract urothelial carcinoma.International urology and nephrology · 2026Article
- Prognostic factors for mortality and recurrence after radical nephroureterectomy for UTUC: a Brazilian cohort study.International urology and nephrology · 2026Article
- Neoadjuvant chemotherapy in upper tract urothelial carcinoma: interpreting durable long-term outcomes in a changing treatment landscape.Translational andrology and urology · 2026Article
- Modern management of locally advanced urothelial carcinoma of the upper urinary tract.World journal of urology · 2026Review
- Comparative insights into upper tract urothelial carcinoma: Aligning Chinese Urological Association and European Association of Urology guidelines with clinical practice.Asian journal of urology · 2026Article
- A Rare Case of Descending Colon Metastasis Following Radical Nephroureterectomy for Left Ureteral Carcinoma: A Case Report and Literature Review.Current oncology (Toronto, Ont.) · 2026Review
- Clinical Trials and Emerging Therapeutic Paradigms in Upper-Tract Urothelial Carcinoma.Cancers · 2026Review
- A bibliometric study and visualization analysis of the current status and perspectives in upper tract urothelial carcinoma.Medicine · 2026Article
- Trends in Treatment and Perioperative Outcomes of Upper Tract Urothelial Carcinoma: The Evolving Role of Lymphadenectomy and Neoadjuvant Chemotherapy.Journal of clinical medicine · 2026Article
- Radiosurgery in Upper Tract Urothelial Carcinoma (UTUC).Cancers · 2026Article
- Tislelizumab combined with gemcitabine plus cisplatin for muscle-invasive upper tract urothelial carcinoma: A retrospective single-center cohort analysis.The Journal of international medical research · 2026Article
- Single versus maintenance intravesical instillation of chemotherapy for intravesical recurrence after radical nephroureterectomy in distal ureteral upper tract urothelial carcinoma: a multicenter retrospective study from China.Frontiers in oncology · 2026Article
- Management and Treatment Strategies for Upper Tract Urothelial Carcinoma: Current Insights.Research and reports in urology · 2026Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 6 institutions in 1 country.
Funding
Abstract
purposeNeoadjuvant chemotherapy (NAC) has proven survival benefits for patients with invasive urothelial carcinoma of the bladder, yet its role for upper tract urothelial carcinoma (UTUC) remains undefined. We conducted a multicenter, single-arm, phase II trial of NAC with gemcitabine and split-dose cisplatin (GC) for patients with high-risk UTUC before extirpative surgery to evaluate response, survival, and tolerability.
methodsEligible patients with defined criteria for high-risk localized UTUC received four cycles of split-dose GC before surgical resection and lymph node dissection. The primary study end point was rate of pathologic response (defined as < ypT2N0). Secondary end points included progression-free survival (PFS), overall survival (OS), and safety and tolerability.
resultsAmong 57 patients evaluated, 36 (63%) demonstrated pathologic response (95% CI, 49 to 76). A complete pathologic response (ypT0N0) was noted in 11 patients (19%). Fifty-one patients (89%) tolerated at least three complete cycles of split-dose GC, 27 patients (47%) tolerated four complete cycles, and all patients proceeded to surgery. With a median follow up of 3.1 years, 2- and 5-year PFS rates were 89% (95% CI, 81 to 98) and 72% (95% CI, 59 to 87), while 2- and 5-year OS rates were 93% (95% CI, 86 to 100) and 79% (95% CI, 67 to 94), respectively. Pathologic complete and partial responses were associated with improved PFS and OS compared with nonresponders (≥ ypT2N any; 2-year PFS 100% and 95%
conclusionNAC with split-dose GC for high-risk UTUC is a well-tolerated, effective therapy demonstrating evidence of pathologic response that is associated with favorable survival outcomes. Given that these survival outcomes are superior to historical series, these data support the use of NAC as a standard of care for high-risk UTUC, and split-dose GC is a viable option for NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.